Description

Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-Kinase/protease–C39H62N10O15—-[1]Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89-94.|[2]Finlayson M. Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015;6:135. Published 2015 Mar 30.|[3]Piotrowicz RS, et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther. 2011;10(11):2072-2082.–220334-14-5–910.97–99.01–O=C(N(CCC1)[C@@H]1C(N[C@@H](CCC(O)=O)C(N[C@H](C(N)=O)CCC(O)=O)=O)=O)[C@H](CCC2)N2C([C@H](CO)NC([C@H](CO)NC([C@H](CCC3)N3C([C@@H](NC(C)=O)CCCCN)=O)=O)=O)=O–Cancer–DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL–PAI-1—-Metabolic Enzyme/Protease–Peptides